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The human immunodeficiency virus (HIV) is a retrovirus
that causes acquired immune deficiency syndrome
(AIDS). Upon infection, the enveloped virus converts its
RNA genome into DNA via reverse transcription. HIV
preferentially infects T-cells, macrophages, and dendritic
cells. Infected T-cells ultimately die, compromising
patients’ immune system and leading to progression to
AIDS. Without treatment, the average life expectancy of
patient is 9 to 11 years following infection.
HIV is a major public health crisis worldwide. It is
transmitted by bodily fluids that contain HIV with a subset
of vulnerable tissues in the recipient, including the mucus
membranes. Successful anti-retroviral therapy targeting
HIV reverse transcriptase has made HIV infection a
manageable disease, however these drugs cannot
eradicate the viral load. Recently, we and others have
been interested in the development of drugs that inhibit
the entry of HIV into the host cell. Entry into host cell is
crucial for infection and its prevention could enable more
robust clearance of virus or preventative treatment of
HIV.
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Human immunodeficiency virus (HIV) infection is a major
public health concern. New strategies that target viral
entry hold promise for preventing infection or for
enhancing the efficacy of existing anti-retroviral therapy.
We have targeted the HIV protein gp41, required for
initial membrane fusion and viral entry, for computational
lead compound development and structural
characterization. We have successfully purified an
engineered version of this protein (gp41-5) that has an
exposed patch that resembles the pre-fusion complex
that is presumed to be an important intermediate in
fusion. We crystallized this protein and collected a
complete dataset, however the crystals suffer from an
unusual order-disorder pathology. Current work is
identifying improved crystallization conditions that will
allow determination of the crystal structure of gp41-5 with
computationally identified compounds that inhibit viral
entry.
A ribbon diagram and helical cartoon of a prior crystal
structure of gp41-5 at 1.5 Å resolution are shown on the
left and right, respectively.2 Gp41-5 contains five alpha
helices, as compared to the six-helix bundle of the native
gp41 protein. The surface of the gp41-5 five helical bundle
left exposed by omitting the sixth helix mimics a pre-fusion
complex and is the predicted binding site of the tested
anti-fusion compounds.3
Purification of gp41-5 protein 
A SDS-PAGE gel of the inclusion body purification of gp41-5
is shown with lanes marked. Raw lysate (RL), supernatant
(S) ,three urea wash steps (U1,2,3), GuHCl-solubilized
protein (GuHCl), purified protein, and the insoluble material
after refolding (IM). Overall, 6 mg, of the purified protein
product was obtained from 1.5 L of cultured E. coli cells.
Light microscopy images taken with polarized light of gp41-
5 crystals. The protein was crystallized in a 1.9M, DL-malic
acid, pH=7.2. The kite-shaped crystals appeared after two-
three weeks of incubation at room temperature.
Composition of the crystals was confirmed by re-dissolving
them and performing mass spectrometry (Dr. Javier
Seravalli, RBC Mass Spectrometry Core).
Diffraction-quality crystals of gp41-5 were obtained from
sparse-matrix screening. A representative image from a
1.2 Å resolution dataset collected at SSRL 12-2 is shown
from a Pilatus PAD detector.
Structure solution by molecular replacement of the
crystal failed. Close analysis of the diffraction data
statistics revealed a pathology in the crystal whereby
non-crystallographic translational symmetry interacting
with pseudosymmetry in the lattice resulted in a
phenomenon called an order-disorder (or lattice
translocation) defect. We have verified that the crystals
contained the target protein by mass spectrometry and
consulted several outside crystallographers to verify that
the data are not solvable.
We have successfully developed an alternative purification
protocol for gp41-5 and obtained crystals of the protein,
however an exotic crystal lattice defect prevents further use
of these crystals. We are currently optimizing protein
purification and screening for additional conditions that will
deliver suitable crystals. We will be working closely with our
computational collaborators in the Rizzo lab at Stony Brook
University to use the structural results to improve compound
design and increase binding affinity. The ultimate goal of this
work is the development of novel drug candidates for the
prevention and treatment of HIV infection.
• Improve protein yield by optimizing purification and 
refolding protocols
• Verify refolding by circular dichroism (CD) spectroscopy
• Re-screen crystallization conditions for alternative crystal 
morphologies that are free of the lattice defect
• Soak in or co-crystallize computationally identified lead 
compounds and determine their structures
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High throughput computational screening has identified 
several lead compounds that are predicted to bind the pre-
fusion exposed patch on gp41 from an initial pool of 
1.4x106 trial compounds.  These compounds have been 
experimentally verified to bind and decrease viral infectivity 
(Dr. Amy Jacobs, SUNY Buffalo, unpublished).  
Role of gp41 in HIV infection 
The viral protein gp41 is essential for HIV entrance into
the host cell. Gp41 is a transmembrane protein that is
bound to gp120. Once gp120 binds to the target cell via
the CD40 receptor, a the formation of a helical bundle
brings HIV and host cell membranes into close proximity,
facilitating fusion and enabling HIV to enter the host cell.
Objective 
The objective of this project is to structurally characterize
the binding of a variety of computationally identified
compounds to the fusogenic inner helical core of gp41
using X-ray crystallography. The compounds being tested
have been developed and characterized by our
collaborators in the research group of Robert Rizzo at
Stony Brook University. The ultimate goal is to improve the
binding affinity and potency of these compounds which
will require experimental structural information.
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